Tivozanib vs sorafenib (targeted agent versus targeted agent)
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Tivozanib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with sorafenib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
- HR 1.25 [0.95, 1.64]1 study · 517 participantsLow